Sorafenib was approved as the first generic in China

Issuing time:2020-08-11 10:06

The Class 4 chemical generic Sorafenib tosylate tablets (trade name: Ligesitai®) developed by Jiangxi Shanxiang Pharmaceutical Co., Ltd., a subsidiary of Qingfeng Pharmaceutical Group, were approved by the National Medical Products Administration on August 5, 2020. NMPA). The launch of Ligesitai®, announcing that we have officially entered the field of liver cancer treatment.

Ligesitai® Sorafenib Tosylate Tablets



Qingfeng Pharmaceutical Group Co.Ltd
Location:8 Zhandong Av., Zhanggong, Ganzhou, Jiangxi Province, China
Phone:+86-0797-5560800,5560600 Fax: +86-0797-5560620